OTC FILING WATCH · LIVEOfficial-source OTC filing intelligence
AUTOMATED SEC FILING DILIGENCE BRIEF
PUBLIC-RECORD DELIVERY

COSCIENS Biopharma Inc.

CIK 0001113423Ticker CSCIDSEC observed OTC

Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.

Open issuer dossier
Reporting & material events130

captured official filings

Registration & offering26

captured official filings

Ownership4

captured official filings

Governance0

captured official filings

WHAT THIS AUTOMATES

One evidence index instead of a manual filing hunt.

It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.

PROFESSIONAL DELIVERY LAYER

What teams can pay to automate next.

Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.

MACHINE-DETECTED FILING CHANGE RADAR

Public registration text delta

Comparing F-1/A filed 2024-04-30 with F-1/A filed 2024-05-14.

Earlier SEC filingLatest SEC filing
324latest comparable sentences
11new-text candidates
13prior-text candidates not found

Tracked-term count changes

Counts are navigation signals, not conclusions. Open both official filings to determine materiality.

  • control17 → 15-2
  • offering27 → 26-1
  • shares189 → 190+1

Candidate disclosure excerpts

Only sentence-level additions or removals containing tracked diligence terms are shown. These are reading cues, not materiality findings.

New in latest filing
  • This prospectus also relates to up to 633,583 Common Shares issuable from time to time upon exercise of the Aeterna Zentaris New Warrants.
  • On May 8, 2024, the last reported sales price of our Common Shares on NASDAQ was $7.80 per share and on TSX was C$10.98 per share.
  • Based on the outstanding securities of Ceapro as of December 31, 2023, and giving effect to the Share Consolidation, it is expected that Aeterna Zentaris will issue up to a maximum of 2,549,231 Common Shares in connection with the Plan of Arrangement (including the Consideration Shares and the Common Shares issuable upon exercis
Present in earlier filing, not found in latest
  • This prospectus also relates to up to 633,606 Common Shares issuable from time to time upon exercise of the Aeterna Zentaris New Warrants.
  • On April 26, 2024, the last reported sales price of our Common Shares on NASDAQ was $1.96 per share and on TSX was C$2.65 per share.
  • Based on the outstanding securities of Ceapro as of December 31, 2023, and giving effect to the Share Consolidation, it is expected that Aeterna Zentaris will issue up to a maximum of 2,549,243 Common Shares in connection with the Plan of Arrangement (including the Consideration Shares and the Common Shares issuable upon exercis

Method: readable plain text is extracted from two official SEC HTML filings, then compared at sentence and tracked-term level. Formatting, exhibit differences and boilerplate may create false positives. This radar is not legal advice, a disclosure completeness opinion or a transaction recommendation.

DOWNLOAD EDITION

Save a project-ready issuer record.

US$29 one time. No subscription and no account. You receive the current printable Evidence Snapshot in this browser immediately after verified payment.

  • Source-linked filing chronology and registration path
  • Machine-detected amendment and tracked-term change view
  • Official-source index for project-file archiving and downloadable CSV export

Secure checkout by PayPal.

AUTOMATED EVIDENCE SNAPSHOT

Save this source-linked record

Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.

Unlock download · US$29
OFFICIAL SEC SUBMISSIONS

Captured filing chronology

Open Evidence Snapshot →
  1. 6-K
    Reporting & material eventsOpen SEC filing →
  2. 6-K
    Reporting & material eventsOpen SEC filing →
  3. 6-K
    Reporting & material eventsOpen SEC filing →
  4. 6-K
    Reporting & material eventsOpen SEC filing →
  5. 6-K
    Reporting & material eventsOpen SEC filing →
  6. 6-K
    Reporting & material eventsOpen SEC filing →
  7. 6-K
    Reporting & material eventsOpen SEC filing →
  8. 6-K
    Reporting & material eventsOpen SEC filing →
  9. 6-K
    Reporting & material eventsOpen SEC filing →
  10. 20-F
    Reporting & material eventsOpen SEC filing →
  11. 6-K
    Reporting & material eventsOpen SEC filing →
  12. EFFECT
    Registration & offeringOpen SEC filing →
  13. EFFECT
    Registration & offeringOpen SEC filing →
  14. EFFECT
    Registration & offeringOpen SEC filing →
  15. EFFECT
    Registration & offeringOpen SEC filing →
  16. EFFECT
    Registration & offeringOpen SEC filing →
  17. 6-K
    Reporting & material eventsOpen SEC filing →
  18. 6-K
    Reporting & material eventsOpen SEC filing →
  19. 6-K
    Reporting & material eventsOpen SEC filing →
  20. 6-K
    Reporting & material eventsOpen SEC filing →
  21. 6-K
    Reporting & material eventsOpen SEC filing →
  22. 6-K
    Reporting & material eventsOpen SEC filing →
  23. 6-K
    Reporting & material eventsOpen SEC filing →
  24. 6-K
    Reporting & material eventsOpen SEC filing →
  25. 6-K
    Reporting & material eventsOpen SEC filing →
  26. 6-K
    Reporting & material eventsOpen SEC filing →
  27. 6-K
    Reporting & material eventsOpen SEC filing →
  28. 6-K
    Reporting & material eventsOpen SEC filing →
  29. 6-K
    Reporting & material eventsOpen SEC filing →
  30. 6-K
    Reporting & material eventsOpen SEC filing →
  31. 6-K
    Reporting & material eventsOpen SEC filing →
  32. 6-K
    Reporting & material eventsOpen SEC filing →
  33. 6-K
    Reporting & material eventsOpen SEC filing →
  34. 6-K
    Reporting & material eventsOpen SEC filing →
  35. 20-F
    Reporting & material eventsOpen SEC filing →
  36. 6-K
    Reporting & material eventsOpen SEC filing →
  37. 6-K
    Reporting & material eventsOpen SEC filing →
  38. 6-K
    Reporting & material eventsOpen SEC filing →
  39. 6-K
    Reporting & material eventsOpen SEC filing →
  40. 6-K
    Reporting & material eventsOpen SEC filing →
  41. 6-K
    Reporting & material eventsOpen SEC filing →
  42. 6-K
    Reporting & material eventsOpen SEC filing →
  43. 6-K
    Reporting & material eventsOpen SEC filing →
  44. 6-K
    Reporting & material eventsOpen SEC filing →
  45. 6-K
    Reporting & material eventsOpen SEC filing →
  46. SC 13D
    OwnershipOpen SEC filing →
  47. 6-K
    Reporting & material eventsOpen SEC filing →
  48. 6-K
    Reporting & material eventsOpen SEC filing →
  49. 6-K
    Reporting & material eventsOpen SEC filing →
  50. 6-K
    Reporting & material eventsOpen SEC filing →
  51. 6-K
    Reporting & material eventsOpen SEC filing →
  52. 20-F/A
    Reporting & material eventsOpen SEC filing →
  53. 6-K
    Reporting & material eventsOpen SEC filing →
  54. 6-K
    Reporting & material eventsOpen SEC filing →
  55. 424B3
    Registration & offeringOpen SEC filing →
  56. 424B3
    Registration & offeringOpen SEC filing →
  57. 424B3
    Registration & offeringOpen SEC filing →
  58. 424B3
    Registration & offeringOpen SEC filing →
  59. 6-K
    Reporting & material eventsOpen SEC filing →
  60. SC 13G
    OwnershipOpen SEC filing →
Evidence boundary

Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.